Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database

AIDS

Volumn 15, Issue 2, 2001, Pages 231-239

  Heath, K V ^a   Hogg, R S ^a   Chan, K J ^a   Harris, M ^a   Montessori, V ^a   O'Shaughnessy, M V ^a   Montaner, J S G ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Antiretroviral agents; Lipodystrophy; Protease Inhibitors; Side Effects

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINASE INHIBITION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CANADA; CHOLESTEROL; COMPLEMENTARY THERAPIES; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; SYNDROME; TRIGLYCERIDES; WASTING SYNDROME;

EID: 0035951473     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00013     Document Type: Article

References (47)

1. Improved survival among HIV infected individuals following initiation of antiretroviral therapy
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell founts of 200 per cubic millimetre or less
3. Studies of body composition and fat distribution in HIV-infected and control subjects
4. Pathogenesis of HIV-1 prolease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
5. Visceral abdominal-fat accumulation associated with use of indinavir
6. 'Protease paunch' in HIV+ persons receiving protease inhibitor therapy: Incidence, risks and endocrinologic evaluation
7. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors
8. Multiple symmetrical lipomatosis associated with protease inhibitor therapy
9. Buffalo hump and facial wasting in HIV
10. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors
11. Lipodystrophy, glucose and lipid metabolism dysfunctions, Aquitaine Cohort, 1999
12. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: Contribution to PI-related LD syndrome
13. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors
14. Changes in body habitus in HIV+ women after initiation of protease inhibitor therapy
15. Factors influencing the evolution of plasma triglyceride in the era of HAART, Aquitaine Cohort 1996-1998
16. Prevalence of lipodystrophy and relation with clinical, anthropometric data and treatment, Aquitaine Cohort, 1999
17. Description of lipodystrophy in the HIV Outpatient Study (HOPS)
18. Diagnosis, prediction, and natural course of HIV-1 protease-lnhibitor-assoclated lipodystrophy, hyperllpidemia, and diabetes mellitus: A cohort study
19. Localized adipose tissue hypertrophy in patients receiving immunodeficiency virus protease inhibitors
20. Buffalo humps associated with protease inhibitors
21. Indinavir-associated lipodystrophy
22. Marked hypertrlglyceridemia associated with ritonavir therapy
23. Antiretroviral safety and durability of ritonavirsaquinavir in protease inhibitor-naive patients in year two of follow-up
24. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors
25. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients
26. Lipid evaluation and glucose metabolism in HIV-infected patients before and after initiation of protease inhibitor therapy
27. Lipid profiles in patients on ritonavir-containing salvage regimens
28. The prevalence of lipodystrophy in an outpatient population
29. Case report of lipodystrophy observations in patients naive of protease inhibitor treatment, Aquitaine Cohort, 1999
30. Dyslipidemia due to HIV infection and its therapy
31. Lipodystrophy related to NRT inhibitors in HAART therapy
32. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
33. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
34. Antlretrovlral therapy in adults: Updated recommendations of the International AIDS Society - USA Panel
35. Consensus meeting on the case definition for lipodystrophy
36. Multidiscipllnary program for detecting and evaluating adverse drug reactions
37. Postmarketing surveillance and adverse drug reactions: Current perspectives and future needs
38. Detecting adverse drug reactions in postmarketing surveillance: Interview validity
39. Detection of adverse drug reactions in a clinical trial using two types of questioning
40. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
41. Metabolic changes in HIV infected patients treated with protease inhibitors
42. The Australian prevalence survey of lipodystrophy syndrome
43. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
44. Lipodystrophy in patients naive to protease inhibitors
45. Mitochondrlal genetics: A paradigm for ageing and degenerative diseases?
46. Determinants of complementary therapy use in HIV-infected individuals already on antiretroviral, anti-opportunistic or prophylactic agents